ReviewOpen Access
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response
Authors
Author Affiliations
London School of Hygiene & Tropical Medicine, Nagasaki University, International Vaccine Institute, Yonsei University, ...
Published InExpert Review of Vaccines
Year2025
Citations17
Abstract
INTRODUCTION: Nipah virus is a high-consequence pathogen that causes sporadic outbreaks with high mortality, and there are currently no vaccines or therapeutics available for Nipah. Vaccine development against Nipah faces challenges due to its current epidemiology with limited outbreak sizes, which impedes the feasibility of conducting vaccine efficacy trials focused on disease endpoints. AREAS COVERED: We review the progress of Nipah vaccine candidates in human clinical trials and highlight the challenges in evaluating the vaccine efficacy due to the sporadic nature of Nipah outbreaks, given the epidemic potential of Nipah virus and its implications for pandemic preparedness. We examine the alternative regulatory pathways, including the US FDA's Animal Rule and EMA's conditional marketing authorization, which permit vaccine approval based on…
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.